BullFrog AI Holdings (BFRGW) Cash & Equivalents (2021 - 2026)
BullFrog AI Holdings' (BFRGW) quarterly Cash & Equivalents came in at $6.9 million in Q2 2026, up 168.29% on a YoY basis from $2.6 million in Q2 2025, and up 216.81% quarter-over-quarter from $2.2 million in Q4 2025.
Analysis
BullFrog AI Holdings (BFRGW) Cash & Equivalents (2021 - 2026) Analysis & Trends
BullFrog AI Holdings (BFRGW) has reported Cash & Equivalents for 6 consecutive years, with $6.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash & Equivalents rose 168.29% year-over-year to $6.9 million; the trailing twelve-month figure through Jun 2026 stood at $6.9 million (up 168.29% YoY), and the FY2025 full-year result was $2.2 million, down 59.83% from the prior year.
- Cash & Equivalents advanced to $6.9 million in Q2 2026 per BFRGW's latest filing, from $2.2 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $7.0 million in Q1 2024 and bottomed at $57670.0 in Q4 2022.
- Historically, Cash & Equivalents has averaged $4.1 million across 5 years, with a median of $4.0 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents soared 4451.29% in 2023, then sank 59.83% in 2025.
- Over 5 years, Cash & Equivalents stood at $57670.0 in 2022, then jumped by 4451.29% to $2.6 million in 2023, then soared by 107.11% to $5.4 million in 2024, then plunged by 59.83% to $2.2 million in 2025, then surged by 216.81% to $6.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $6.9 million, $2.2 million, and $2.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.66 Bn | 197.67 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn | 6.14 Bn |
| 4 | Regeneron Pharmaceuticals | 82.63 Bn | 74.64 Bn | 3.93 Bn | 2.46 Bn |
| 5 | Argenx Se | 61.60 Bn | 56.41 Bn | 1.37 Bn | 3.58 Bn |
| 6 | Moderna | 54.55 Bn | 49.41 Bn | 52.00 Mn | 1.72 Bn |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.71 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Biogen | 31.26 Bn | 29.97 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn | 1.25 Bn |
| 10 | BullFrog AI Holdings | 1.84 Mn | -5.08 Mn | 106,899.00 | 6.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.92 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 2.58 Mn |
| Mar 31, 2025 | 3.80 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | 5.61 Mn |
| Mar 31, 2024 | 7.01 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 3.86 Mn |
| Jun 30, 2023 | 5.46 Mn |
| Mar 31, 2023 | 5.42 Mn |
| Dec 31, 2022 | 57,670.00 |
| Dec 31, 2021 | 10,014.00 |